Communiqués Fulcrum Therapeutics, Inc.

Actions

FULC

US3596161097

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
3,860 ^USD	0,00%		-1,28%	-65,87%

17/08	Fulcrum fusionne avec Slate dans le cadre d'une transaction entièrement en actions après l'échec d'un candidat-médicament	RE
17/08	Transcript : Fulcrum Therapeutics, Inc., Slate Medicines, Inc. - M&A Call

Communiqués

19/08	Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC	BU
17/08	Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies	GL
04/06	FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud	BU
01/06	Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review	GL
08/05	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
27/04	Fulcrum Therapeutics : Corporate Presentation - April 2026	PU
27/04	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026	GL
27/04	Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors	GL
20/04	Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET	GL
19/03	MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease	GL
06/03	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
03/03	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference	GL
24/02	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025	GL
24/02	Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease	GL
17/02	Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease	GL
06/02	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
14/01	Fulcrum Therapeutics : Corporate Presentation - January 2026	PU
09/01	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
07/01	Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference	GL
10/12	Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants	GL
08/12	Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock	GL
08/12	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06/12	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting	GL
05/12	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/12	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025	GL